STXS logo

STXS
Stereotaxis Inc

2,056
Mkt Cap
$190.59M
Volume
335,616.00
52W High
$3.59
52W Low
$1.70
PE Ratio
-7.99
STXS Fundamentals
Price
$2.01
Prev Close
$1.95
Open
$1.94
50D MA
$1.89
Beta
1.20
Avg. Volume
414,078.54
EPS (Annual)
-$0.2519
P/B
13.24
Rev/Employee
$247,152.67
$206.46
Loading...
Loading...
News
all
press releases
ISRG's Ion Platform: A Major Growth Engine in Lung Cancer Care?
ISRG's Ion platform saw 39% procedure growth in Q1, with new clinical data strengthening its role in lung cancer diagnosis.
News Placeholder
More News
News Placeholder
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +25.00% and -30.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Inogen (INGN) Reports Q1 Loss, Beats Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of -25.00% and +3.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of +14.30% and +6.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Integra LifeSciences (IART) Beats Q1 Earnings and Revenue Estimates
Integra (IART) delivered earnings and revenue surprises of +32.78% and +2.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
STXS stock gains after first U.S. MAGiC procedures, marking a key milestone in robotic cardiac care and boosting its growth outlook.
News Placeholder
STXS to Acquire Robocath to Lead in Endovascular Robotics Market
Stereotaxis expands in robotic surgery with Robocath acquisition, aiming to build a comprehensive endovascular platform and unlock growth opportunities.
News Placeholder
STXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery
STXS jumps on FDA clearance of Synchrony system, a 4K platform integrating cath lab tech with cloud connectivity to boost workflow, precision and digital surgery.
News Placeholder
Intuitive Surgical Under Pressure in China: Can It Defend Its Position?
ISRG faces rising pricing pressure in China as local rivals gain ground, but its ecosystem, local manufacturing and disciplined pricing aim to defend its position.
News Placeholder
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
Stereotaxis (STXS) delivered earnings and revenue surprises of +5.21% and -5.55%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available